Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor.

To take full advantage of modern immunotherapy, we need to increase the percentage of patients that respond to treatment. One way to increase the response rate is to more closely mimic a natural immune response. This is a three-step process that incorporates different signals to trigger activation, maintenance, and long-term immune memory. Modern immunotherapies typically trigger one of these stages. Janux, on the other hand, is developing drugs that provide multiple immune signals to strengthen and sustain the anti-cancer drug response.

Unfortunately, immunotherapies often fail to maximize patient responses due to toxicity and safety issues. Relatedly, a key problem with immunotherapies is their inherent ability to generate a systemic immune response that not only attacks tumors, but also attacks healthy tissue. This non-specific activity often leads to significant toxicities and in turn limits the amount of drug that can be dosed. These drug-dosing limitations and safety issues adversely impact the ability to achieve full anti-tumor responses.


At Janux, we are developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. Furthermore, Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. We believe that combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient responses.